Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients
Phase II Study of Oxaliplatin / Irinotecan / Bevacizumab Followed by Docetaxel / Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
A PHASE2 clinical study on Gastric Cancer and Unresectable, this trial is completed. The trial is conducted by Arbeitsgemeinschaft medikamentoese Tumortherapie and has accumulated 10 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Aug 2020 — Dec 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jan 2017 — Jun 2017 [monthly]
Unknown Status PHASE2
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Pfizer
- Roche Pharma AG
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .